- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Model N Announces Deal Management for Life Sciences
New solution addresses pricing pressures and streamlines order-to-cash process.
Model N has launched a new Deal Management solution, which connects field sales professionals with operations teams to support the execution and management of the order-to-cash process.
The software-as-a-service solution (SaaS) helps life sciences companies “more efficiently execute contracts by delivering real-time visibility into tiered pricing and rebate data, while providing actionable sales analytics directly to field sales teams,” states the company.
Among the reported benefits for life sciences manufacturers, Deal Management
- improves topline revenue by accessing intelligence previously not accessible to field sales teams
- enhances customer relationships by proactively communicating rebate, tiered pricing and capital equipment status, providing an opportunity to course-correct
- maximizes the Salesforce investment by driving the sales team to Salesforce to access intelligence and manage deals, and
- increases efficiency with field sales and commercial operations teams, decreasing the time to execute and creating more time for value-added tasks.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
